Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04901936 · ClinicalTrials.gov registry record · Phase 2
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Phase 2 study of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Paroxysmal Hemoglobinuria, sponsored by Apellis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 12
- Study locations
NCT04901936: Recruiting Phase 2 study of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Paroxysmal Hemoglobinuria, sponsored by Apellis Pharmaceuticals.
NCT04901936 is a Phase 2 study of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Paroxysmal Hemoglobinuria that is actively recruiting participants, run by Apellis Pharmaceuticals. The registered enrollment target is 12 participants, below the 123-participant average among 5 other Paroxysmal Nocturnal Hemoglobinuria (PNH) trials with a reported enrollment target (90% lower). The trial reports 12 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04901936, a Phase 2 study of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Paroxysmal Hemoglobinuria, is actively recruiting participants, sponsored by Apellis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).
Conditions Studied
Interventions
- DRUG Pegcetacoplan
Study Locations (12)
Other
- Motol University Hospital - Prague
- Robert-Debré Hospital Paris - Paris
- Hospital Ampang - Ampang
- Radboud University Hospital Nijmegen - Nijmegen
- University Medical Center Utrecht - Utrecht
- University Children's Hospital - Belgrade
- University Hospital Vall d'Hebron - Barcelona
- University Hospital 12 de Octubre - Madrid
- Phramongkutklao Hospital and College of Medicine - Bangkok
- Maharaj Nakorn Chiang Mai hospital - Chiang Mai
- St. Mary's Hospital - London
Georgia
- Children's Hospital of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-02-04 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT04901936 shows while recruiting
NCT04901936 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 123-participant average among 5 other Paroxysmal Nocturnal Hemoglobinuria (PNH) trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Paroxysmal Nocturnal Hemoglobinuria (PNH) appearing as the primary indexed condition, and to 1 intervention - of which Pegcetacoplan is the first listed.
NCT04901936 lists 12 locations in 2 states (Other, Georgia).
Frequently Asked Questions
What is clinical trial NCT04901936 about?
NCT04901936 is a clinical study titled "A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)". The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).
What is the current status of trial NCT04901936?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-02-04. Estimated completion is 2028-12.
What conditions does trial NCT04901936 study?
This clinical trial studies the following conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria.
What interventions are being tested in trial NCT04901936?
The interventions under investigation include: Pegcetacoplan (DRUG).
Who is sponsoring clinical trial NCT04901936?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04901936 being conducted?
This trial has 12 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
RECRUITING · Phase 2
-
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
RECRUITING
-
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
RECRUITING · Phase 3
-
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
COMPLETED · Phase 3
-
ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI